On Jan. 16, 2012, the U.S. Food and Drug Administration (FDA) approved Flublok, the first trivalent influenza vaccine made using an insect virus (baculovirus) expression system and recombinant DNA technology. This new technology may enable a faster start-up of vaccine manufacturing should a pandemic occur. Flubok is approved for people 18 through 49 years of age. Read more.
FDA approves seasonal flu vaccine made using novel technology
Share